CPH Group

Home CPH

CPH Group achieves stable sales of CHF 176 million and an EBITDA of CHF 28.3 million, with a margin of 16.1%—up from 15.0% in 2025. The company maintains a 7.3% free cash flow margin. Perlen Packaging delivers strong first-half results, while Zeochem’s growth pace slows slightly. The board approves a higher dividend payout ratio.

Jul 2026CPHNews article

CPH Group reports **CHF 334 million in net sales** for 2025, up from CHF 323 million the prior year. The company’s **EBITDA drops 6.5% to CHF 50.3 million**, yielding a 15.0% margin. Despite challenges, CPH Group proposes maintaining a **CHF 2.00 dividend per share** for shareholder approval.

Feb 2026CPHNews article

CPH Group revises its 2025 earnings forecast, targeting **CHF 50 million in EBITDA** (down from CHF 53.8 million in 2024). The company cites a **slowdown in the global pharmaceutical packaging market**, adverse currency effects, and higher depreciation and financing costs as key factors. One-time income from 2024 is also absent, contributing to a projected **EBIT and net result below prior-year levels**.

Nov 2025CPHNews article

Zeochem, part of the CPH Group, has agreed to acquire all substantial assets of SiliCycle Inc., a Canadian manufacturer specializing in high-value chromatography gels for the pharmaceutical industry. The deal advances CPH Group’s global expansion strategy by integrating SiliCycle’s product line. The acquisition targets pharmaceutical companies relying on chromatography solutions for drug development and production.

Jul 2025CPHNews article